A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Metabolism of GLPG3970 in Healthy Male Subjects Following a Single Oral Dose of GLPG3970 Relative to an Intravenous [14C]GLPG3970 Microtracer and Single Oral [14C]GLPG3970 Administration
Latest Information Update: 26 Jul 2021
At a glance
- Drugs GLPG 3970 (Primary) ; GLPG 3970; GLPG 3970
- Indications Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Galapagos NV
- 22 Jul 2021 Status changed from recruiting to completed.
- 11 Jun 2021 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
- 11 Jun 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jul 2021.